Recent research demonstrates that dual silencing of VISTA and CTLA‐4 markedly enhances anti‐tumor immune responses, improves the inflammatory cytokine milieu, and inhibits tumor progression, offering a novel approach to address TME heterogeneity [60]. This evidence concerns the gene CTLA4 and neoplasm.